Gastric Cancer Market to Exceed USD 700 Million in HER2+ Segment by 2034 Across 7MM, Backed by 211,550 Annual Cases and 15+ Key Therapies | DelveInsight

Gastric cancer is the fifth most common malignancy worldwide, with incidence varying by region and highest rates reported in Eastern Asia and Eastern Europe. Japan records the highest burden among the 7MM, with about 129,500 cases in 2024. Many patients, particularly in Western countries, are diagnosed at advanced (Stage IV) stages, while Japan detects more cases early (Stage I). In the US, around 35% present with metastatic disease at diagnosis, and men are 2.2 times more likely to be affected than women.
Standard treatment includes gastrectomy and platinum-based chemotherapy, though targeted and immunotherapies are expanding options. Approved therapies include ENHERTU, OPDIVO, KEYTRUDA, CYRAMZA, HERCEPTIN, VYLOY, and TEVIMBRA. Recent approvals, including VYLOY in Japan and TEVIMBRA in the US, highlight continued innovation. Multiple companies are advancing promising pipeline therapies, signaling strong future growth in the gastric cancer market.

DelveInsight's "Gastric Cancer Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Gastric Cancer, historical and forecasted epidemiology as well as the Gastric Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Gastric Cancer, offering comprehensive insights into the Gastric Cancer revenue trends, prevalence, and treatment landscape. The report delves into key Gastric Cancer statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Gastric Cancer therapies. Additionally, we cover the landscape of Gastric Cancer clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Gastric Cancer treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Gastric Cancer space.

To Know in detail about the Gastric Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gastric Cancer Market Forecast @ https://www.delveinsight.com/report-store/gastric-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key facts of the Gastric Cancer Market Report:
• The Gastric Cancer market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In 2023, the United States held the largest market share for gastric cancer among the 7MM. Over half of all new gastric cancer cases globally are found in China and Japan, with Japan reporting the highest number of incident cases within the 7MM. Males are more frequently diagnosed with gastric cancer than females.
• Several medications are approved for treating gastric cancer, including ENHERTU (AstraZeneca/Daiichi Sankyo), CYRAMZA (Eli Lilly), OPDIVO (Bristol-Myers Squibb), KEYTRUDA (Merck), AYVAKIT (Blueprint Medicines), HERCEPTIN (Genentech), and others. The pipeline for new treatments is promising, featuring emerging drugs like Bemarituzumab, Zolbetuximab, and Lenvatinib.
• In February 2026, HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to HCB101 for the treatment of gastric cancer. The designation covers gastric cancer broadly, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative subtypes. This milestone underscores the significant unmet medical need in gastric cancer and provides important regulatory support for the continued clinical development of HCB101 in this patient population.
• In January 2026, Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive efficacy and safety results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera® (zanidatamab-hrii) in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra® (tislelizumab), as first-line treatment for adults with HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including cancers of the stomach, gastroesophageal junction and esophagus.
• In February 2026, AstraZeneca's Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) has been recommended for approval in the European Union (EU) for the treatment of adult patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers. The regimen includes neoadjuvant Imfinzi in combination with chemotherapy before surgery, followed by adjuvant Imfinzi in combination with chemotherapy, then Imfinzi monotherapy.
• In December 2025, Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in gastric cancer evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody. The study will compare cadonilimab plus chemotherapy against chemotherapy with or without nivolumab as first-line treatment for HER2-negative, unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma.
• In October 2025, Dewpoint Therapeutics, the leader in condensate biology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to DPTX3186, its first-in-class condensate modulator for the treatment of gastric cancer. The designation follows the recent opening of Dewpoint's Investigational New Drug (IND) application for DPTX3186, marking the company's transition to a clinical-stage biotech and the first human study of a condensate-modulating therapeutic.
• In March 2025, Daiichi Sankyo announced a Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction (GEJ) Cancer (Destiny-Gastric05)
• In March 2025, AstraZeneca announced a Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants With HER2-expressing Gastric Cancer (DESTINY-Gastric-03)
• In March 2025, SUNHO(China)BioPharmaceutical CO., Ltd announced a Phase II/III Clinical Study Evaluating IAH0968 in Combination or Not in Combination With the CAPEOX Regimen in HER2-expressing Advanced/Metastatic Solid Tumors and Gastric Cancer
• In March 2025, Chimeric Therapeutics announced a Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 (CDH17) Chimeric Antigen Receptor (CAR) T Cell Therapy for the Treatment of Relapsed or Refractory Gastrointestinal Cancers
• In January 2025, the US Food and Drug Administration (FDA) approved BeiGene's PD-1 inhibitor, Tevimbra (tislelizumab-jsgr), as a first-line combination therapy for advanced gastric cancer.
• In October 2024, Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved VYLOYTM (zolbetuximab-clzb) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive as determined by an FDA-approved test.1 VYLOY is the first and only CLDN18.2-targeted therapy approved in the U.S.
• In March 2024, Japan's Ministry of Health, Labour and Welfare (MHLW) approved VYLOY (zolbetuximab), an anti-claudin 18.2 monoclonal antibody for patients with CLDN18.2 positive, unresectable, advanced, or recurrent gastric cancer. This makes VYLOY the first and only therapy targeting CLDN18.2 to gain approval from any regulatory authority worldwide.
• In February 2024, the US FDA accepted a Biologics License Application (BLA) for TEVIMBRA, to be used in combination with fluoropyrimidine- and platinum-based chemotherapy for patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, with an expected FDA action date in December 2024.
• In 2022, Japan recorded the highest number of new gastric cancer cases among the 7MM, totaling 126,724.
• In the US, approximately 37% of gastric cancer cases are identified at advanced stages.
• Key Gastric Cancer Companies: AstraZeneca, Daiichi Sankyo, Bristol-Myers Squibb, Merck & Co., Blueprint Medicines, Genentech, Astellas Pharma, BeiGene, Jazz Pharmaceuticals, Zymeworks, ALX Oncology, Pfizer, and others
• Key Gastric Cancer Therapies: ENHERTU (Fam-Trastuzumab Deruxtecan-nxki), OPDIVO, Bemarituzumab, TEVIMBRA, and others
• The Gastric Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gastric Cancer pipeline products will significantly revolutionize the Gastric Cancer market dynamics.

Gastric Cancer Overview
Gastric cancer develops when cancer cells form in the stomach lining, which consists of five layers: mucosa, submucosa, muscularis propria, subserosa, and serosa. The tumor's location and the layers it invades are crucial for determining the cancer stage, which influences treatment options and prognosis. As the cancer progresses deeper into the layers, more extensive treatment becomes necessary.

Diagnosis involves reviewing medical history, physical exams, and tests for anemia or bleeding. Key diagnostic methods include upper endoscopy with biopsy and barium swallow x-rays, along with advanced imaging techniques like CT scans and MRIs to assess cancer staging and guide treatment.
Treatment for gastric cancer is customized based on the cancer's stage and location. Surgical options range from endoscopic mucosal resection for early cases to partial or total gastrectomy for advanced cancer. Neoadjuvant and adjuvant therapies, including chemotherapy and chemoradiation, aim to shrink tumors and reduce recurrence.

Other interventions may involve stent placement, laser therapy, and gastrojejunostomy to restore digestive function.
Additional treatment options include radiation, systemic chemotherapy, targeted therapies, immunotherapy, and hyperthermic intraperitoneal chemotherapy (HIPEC). Various approved medications, such as ENHERTU, CYRAMZA, OPDIVO, KEYTRUDA, AYVAKIT, and HERCEPTIN, are available for treating gastric cancer.

The report offers a comprehensive view of gastric cancer's pathophysiology and diagnosis, including a real-world example of a patient's journey from symptom onset to diagnosis and treatment.

Get a Free sample for the Gastric Cancer Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/report-store/gastric-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Gastric Cancer Epidemiology
In 2024, approximately 211,550 new cases of gastric cancer, including gastroesophageal junction (GEJ) cancers, were reported across the seven major markets (7MM), with incidence projected to rise by 2034. Japan accounted for the largest share, reporting about 129,500 new cases. In the United States, nearly 37% of patients are diagnosed at a distant (metastatic) stage, indicating late detection. The average age at diagnosis is 68 years, and roughly 60% of newly diagnosed patients are aged 65 or older, highlighting the significant impact of gastric cancer on the elderly population.

Gastric Cancer Epidemiology Segmentation:
The Gastric Cancer market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Diagnosed Prevalence of Gastric Cancer in Adults
• Diagnosed Prevalence of Gastric Cancer in Pediatrics
• Diagnosed Prevalence of Gastric Cancer by Types
• Diagnosed Prevalence of Gastric Cancer by Location
• Diagnosed Prevalence of Gastric Cancer by Severity

Gastric Cancer Drugs and Therapies
• KEYTRUDA (pembrolizumab): Merck
• ENHERTU (trastuzumab deruxtecan): Daiichi Sankyo and AstraZeneca
• OPDIVO (nivolumab): Bristol-Myers Squibb
• CYRAMZA (ramucirumab): Eli Lilly
• Bemarituzumab: Amgen
• ZIIHERA (zanidatamab): Jazz Pharmaceuticals, BeiGene, and Zymeworks
• Rilvegostomig: AstraZeneca
• AZD0901: AstraZeneca
• Evorpacept (ALX148): ALX Oncology
• TUKYSA (tucatinib): Pfizer
• A166 (Trastuzumab botidotin): KLUS Pharma
• ELVN-002: Enliven Therapeutics
• ARX788: Ambrx and NovoCodex

Gastric Cancer Key Companies
AstraZeneca (NASDAQ: AZN), Daiichi Sankyo (TSE: 4568), Bristol-Myers Squibb (NYSE: BMY), Merck & Co. (NYSE: MRK), Blueprint Medicines (NASDAQ: BPMC), Genentech, Astellas Pharma (TSE: 4503), BeiGene (NASDAQ: ONC; HKEX: 6160), Jazz Pharmaceuticals (NASDAQ: JAZZ), Zymeworks (NASDAQ: ZYME), ALX Oncology (NASDAQ: ALXO), Pfizer (NYSE: PFE), and others

Discover more about therapies set to grab major Gastric Cancer market share https://www.delveinsight.com/sample-request/gastric-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Gastric Cancer Market Outlook
The gastric cancer treatment landscape is evolving rapidly, supported by advances in targeted therapies and immunotherapies. While platinum-based chemotherapy and gastrectomy remain foundational treatments for early-stage disease, newer precision medicines are reshaping care, particularly in advanced settings.

ENHERTU, a HER2-targeted antibody-drug conjugate, gained FDA approval in 2021 and European approval in 2022 for HER2-positive advanced gastric cancer, expanding treatment options. OPDIVO was also approved in 2021 as adjuvant therapy for esophageal and gastroesophageal junction cancers. Promising pipeline agents include bemarituzumab (FGFR2b-targeted, FDA Breakthrough Therapy designation) and zolbetuximab, the first Claudin 18.2-targeted therapy approved in Japan.

Major companies such as Amgen, ALX Oncology, Jazz Pharmaceuticals, BeiGene, Zymeworks, AstraZeneca, Pfizer, and others are advancing late-stage candidates in gastric cancer.

The HER2-positive gastric cancer market across the 7MM reached approximately USD 700 million in 2024 and is expected to grow through 2034. Germany leads the EU4 markets, while the UK represents the smallest share. In 2024, trastuzumab plus chemotherapy generated about USD 140 million in US revenue, while ENHERTU is projected to become the leading revenue-generating therapy in Europe by 2034.

Scope of the Gastric Cancer Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Gastric Cancer Companies: Roche, Bristol Myers Squibb, Chugai Pharmaceuticals, Taiho Pharmaceuticals, Merck, Roche, Novartis, and others
• Key Gastric Cancer Therapies: ENHERTU (Fam-Trastuzumab Deruxtecan-nxki), OPDIVO, Bemarituzumab, TEVIMBRA, and others
• Gastric Cancer Therapeutic Assessment: Gastric Cancer current marketed and Gastric Cancer emerging therapies
• Gastric Cancer Market Dynamics: Gastric Cancer market drivers and Gastric Cancer market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Gastric Cancer Unmet Needs, KOL's views, Analyst's views, Gastric Cancer Market Access and Reimbursement

To know more about Gastric Cancer companies working in the treatment market, visit @ Gastric Cancer Clinical Trials and Therapeutic Assessment @ https://www.delveinsight.com/sample-request/gastric-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Gastric Cancer Market Report Introduction
2. Executive Summary for Gastric Cancer
3. SWOT analysis of Gastric Cancer
4. Gastric Cancer Patient Share (%) Overview at a Glance
5. Gastric Cancer Market Overview at a Glance
6. Gastric Cancer Disease Background and Overview
7. Gastric Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Gastric Cancer
9. Gastric Cancer Current Treatment and Medical Practices
10. Gastric Cancer Unmet Needs
11. Gastric Cancer Emerging Therapies
12. Gastric Cancer Market Outlook
13. Country-Wise Gastric Cancer Market Analysis (2020-2034)
14. Gastric Cancer Market Access and Reimbursement of Therapies
15. Gastric Cancer Market Drivers
16. Gastric Cancer Market Barriers
17. Gastric Cancer Appendix
18. Gastric Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.